JP2023529099A - 修飾タンパク質およびタンパク質分解誘導薬 - Google Patents

修飾タンパク質およびタンパク質分解誘導薬 Download PDF

Info

Publication number
JP2023529099A
JP2023529099A JP2022573579A JP2022573579A JP2023529099A JP 2023529099 A JP2023529099 A JP 2023529099A JP 2022573579 A JP2022573579 A JP 2022573579A JP 2022573579 A JP2022573579 A JP 2022573579A JP 2023529099 A JP2023529099 A JP 2023529099A
Authority
JP
Japan
Prior art keywords
ddb1
optionally substituted
protein
alkyl
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022573579A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023529099A5 (https=
Inventor
リュー，ジン
ブルーノ プリュー，マイケル
ランドロフ リー，マシュー
ハン，シャオラン
チェン，リチュン
ジャン，チョンウェイ
ワン，ジャリャン
Original Assignee
クルゲン（シャンハイ），インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by クルゲン（シャンハイ），インク． filed Critical クルゲン（シャンハイ），インク．
Publication of JP2023529099A publication Critical patent/JP2023529099A/ja
Publication of JP2023529099A5 publication Critical patent/JP2023529099A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
JP2022573579A 2020-05-28 2021-05-28 修飾タンパク質およびタンパク質分解誘導薬 Pending JP2023529099A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020092941 2020-05-28
CNPCT/CN2020/092941 2020-05-28
CNPCT/CN2021/081554 2021-03-18
CN2021081554 2021-03-18
PCT/CN2021/096782 WO2021239117A1 (en) 2020-05-28 2021-05-28 Modified proteins and protein degraders

Publications (2)

Publication Number Publication Date
JP2023529099A true JP2023529099A (ja) 2023-07-07
JP2023529099A5 JP2023529099A5 (https=) 2024-06-04

Family

ID=78722770

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022573579A Pending JP2023529099A (ja) 2020-05-28 2021-05-28 修飾タンパク質およびタンパク質分解誘導薬

Country Status (5)

Country Link
US (2) US20230057177A1 (https=)
EP (1) EP4157888A4 (https=)
JP (1) JP2023529099A (https=)
CN (1) CN116472292A (https=)
WO (1) WO2021239117A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022010924A2 (pt) 2019-12-06 2022-09-06 Vertex Pharma Tetra-hidrofuranos substituídos como moduladores de canais de sódio
CN115197164B (zh) * 2021-04-12 2025-04-01 杜心赟 新型噻唑类化合物及其制备方法和用途
SMT202500481T1 (it) 2021-06-04 2026-01-12 Vertex Pharma N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio
IL312013A (en) * 2021-10-14 2024-06-01 Cullgen Shanghai Inc Modified proteins and protein degraders
JP2026501188A (ja) * 2022-12-16 2026-01-14 杭州阿諾生物医薬科技有限公司 サイクリンｋ分解剤及びその使用
WO2024183798A1 (en) * 2023-03-07 2024-09-12 Cullgen Inc. Compounds and methods of treating cancers
WO2025054361A1 (en) * 2023-09-05 2025-03-13 Apellis Pharmaceuticals, Inc. Complement inhibition

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144832A1 (en) * 2017-02-03 2018-08-09 Celgene Corporation Methods for measuring small molecule affinity to cereblon
WO2019034332A1 (en) * 2017-08-18 2019-02-21 Cambridge Enterprise Limited MODULAR BINDING PROTEINS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520583D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
US11691984B2 (en) * 2018-10-12 2023-07-04 The Scripps Research Institute Compounds and methods for DCAF-mediated protein degradation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018144832A1 (en) * 2017-02-03 2018-08-09 Celgene Corporation Methods for measuring small molecule affinity to cereblon
WO2019034332A1 (en) * 2017-08-18 2019-02-21 Cambridge Enterprise Limited MODULAR BINDING PROTEINS

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KAZUMA SEKIBA ET AL., CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY, vol. 7, no. 2, JPN6025028359, 2019, pages 297 - 312, ISSN: 0005758747 *

Also Published As

Publication number Publication date
US20240066136A1 (en) 2024-02-29
WO2021239117A1 (en) 2021-12-02
EP4157888A4 (en) 2024-07-10
EP4157888A1 (en) 2023-04-05
CN116472292A (zh) 2023-07-21
US20230057177A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
JP2023529099A (ja) 修飾タンパク質およびタンパク質分解誘導薬
CN108349940B (zh) 布鲁顿酪氨酸激酶抑制剂
RU2135471C1 (ru) Гетероциклические соединения, способ их получения, композиция на их основе и способ противодействия тахикининовым рецепторам
ES2694754T3 (es) Derivados novedosos de pirrolidina como inhibidores de MetAP-2
CA3228601A1 (en) Novel plk1 degradation inducing compound
JP2005506304A (ja) ホスホジエステラーゼ（ｐｄｅ）７の融合ヘテロ環阻害剤
KR20090106604A (ko) 축합 피리딘 화합물
RU2666730C2 (ru) Диазольные лактамы
KR20190045335A (ko) Pad4의 헤테로아릴 억제제
SK4322003A3 (en) Aza- and polyaza-naphthalenyl carboxamides useful as HIV integrase inhibitors
TW201630915A (zh) 一類ｔｏｌｌ樣受體７激動劑
CA2965517A1 (en) Indole carboxamides compounds useful as kinase inhibitors
EP3652168A1 (en) 5-membered and bicyclic heterocyclic amides as inhibitors of rock
JP2017523204A (ja) 認知向上のために用いる新規化合物
US20250235543A1 (en) Modified proteins and protein degraders
JP2013510191A (ja) Ｎ−２ピラゾロスピロケトンアセチル−ＣｏＡカルボキシラーゼ阻害薬
WO2018229543A2 (en) Therapeutic inhibitory compounds
JP2007217408A (ja) 医薬組成物
CA3201756A1 (en) Methods and compounds for modulating myotonic dystrophy 1
US20210403479A1 (en) Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
JP2023541464A (ja) ２－アミノ－３－カルボニルイミダゾピリジン及びピラゾロピリジン化合物
EP2981264B1 (en) Inhibitors of bruton's tyrosine kinase
TW202500189A (zh) 雙官能降解劑及其用途
CA3230941A1 (en) Ahr agonists
JP2008510734A (ja) キナーゼ阻害剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230829

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251009

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251222

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260316